📈 Key focus areas include:
* Expanding the list of vital medicines, including innovative drugs
* Balancing state guarantees with commercial availability
* Addressing supply chain stability and pricing pressure
💬 The session raises pressing questions:
* How to optimize government procurements without sacrificing innovation?
* What happens when suppliers exit the market or resist price drops?
* How can businesses help cover hard-to-reach regions and rare disease cases?
💱 As the state intensifies efforts to phase out imports, participants will explore new partnerships, pricing models, and regulatory strategies to sustain broad coverage.
📩 Join this vital discussion on safeguarding Russia’s pharmaceutical future through affordability, innovation, and strategic collaboration.